HOME >> MEDICINE >> NEWS
Serendipity versus planning - cancer drugs of the future?

Delegates at the European Breast Cancer Conference (EBCC-5) were given two examples of promising new drugs to watch in the future - raloxifene and lapatinib.

New anticancer drugs are usually developed specially for the job, but occasionally they are borrowed from another field of medicine, and applied speculatively in cancer. Tamoxifen was designed as an anti-oestrogen, based on the observation that at least a third of breast cancers depend on female sex hormones such as oestrogen for survival. Tamoxifen has shown to be an exceptionally effective molecule in cancer treatment; It was never planned to be a preventive agent, but so it has proved to be! It is now licensed to be used to prevent breast cancer in certain women at high risk of the disease.

Contrast this with raloxifene, a drug first developed to treat osteoporosis in women. A selective benzothiophene oestrogen receptor modulator (SERM), raloxifene binds to oestrogen receptors as a mixed oestrogen and anti-oestrogen effect. It functions as an oestrogen sometimes (in bones and on lipid metabolism) and as an anti-oestrogen in other target tissues (endometrium and breast). So, it has the potential for producing some of oestrogen's beneficial effects without producing its adverse effects. In a trial of its use in osteoporosis, it appeared to have another completely different effect, namely prevention of new hormone dependant breast cancers.

Results from the MORE (The Multiple Outcomes of Raloxifene Evaluation) study of 7,705 women that were randomised to raloxifene or placebo demonstrated that among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during three years of treatment with raloxifene.

Stronger evidence on the safety and efficacy of raloxifene is awaited from the STAR Trial. This trial includes almost 20,000 postmenopausal women in the US who are at increased risk of breast cancer to determine whether raloxifene is as e
'"/>

Contact: EBCC-5 Press Office
stephanie.makin@toniclc.com
33-493-928-402
Federation of European Cancer Societies
24-Mar-2006


Page: 1 2 3

Related medicine news :

1. Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention
2. Quality versus quantity -- transforming kidney transplant policy
3. Fixed versus growth intelligence mindsets: Its all in your head, Dweck says
4. Mechanism of black cohosh versus hot flashes revealed
5. IMRT versus 3D CRT for prostate cancer, new long-term data assesses side effects
6. Adolescent condom use with casual versus main partners
7. Study shows rituximab effective in treating chronic graft-versus-host disease
8. Gap widens between optimal versus actual cholesterol levels
9. CT colonography versus colonoscopy for colorectal cancer
10. The economics of prescription drugs versus OTC
11. Inverse planning system improves brachytherapy treatment for prostate and other cancers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Serendipity versus planning cancer drugs the future

(Date:7/2/2015)... ... July 02, 2015 , ... B. E. Smith, the ... to lead a national chief operating officer recruitment for Nicklaus Children’s ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/2/2015)... ... ... AvePoint Public Sector, Inc., a wholly owned subsidiary of ... it was named the recipient of the 2015 GTRA ConVurge Tech Award for Excellence ... Government Technology Research Alliance (GTRA), was presented June 29 during the ConVurge Honorary Awards ...
(Date:7/2/2015)... ... July 02, 2015 , ... As the world becomes more connected through ... they interact with products in their everyday lives. Technology can now help homeowners gain ... home entertainment and safety, as well as making kitchen tasks simpler. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... A Board ... CoolSculpting Plus, an advanced approach to body contouring. CoolSculpting Plus combines CoolSculpting® ... About the basic CoolSculpting procedure:, The CoolSculpting procedure is the only ...
(Date:7/2/2015)... ... July 02, 2015 , ... Denver-based SlimGenics Weight Control ... was named No. 14 on ColoradoBiz magazine’s Top 100 Woman-Owned Companies list. ColoradoBiz ... been recognized. The award identifies outstanding woman-owned businesses that demonstrate excellence and success ...
Breaking Medicine News(10 mins):Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 2Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 3Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 4Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 2Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 3Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 4Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3
(Date:7/2/2015)... Conn. , July 2, 2015 Numotion,s ... Executive Officer announced that Tamas Feitel has ... Feitel joins Numotion after a highly successful 18 year ... leadership roles driving strategy, profitability, and productivity to result ... most recent position was Chief Financial Officer for GE ...
(Date:7/2/2015)... , July 2, 2015   Decision Resources ... retinal specialists identify less frequent dosing as the ... due to the burden on both patients and ... growth factor (VEGF) injections, which are the current ... abicipar pegol, which is in development for dosing ...
(Date:7/2/2015)... The report "Silage Inoculants & Enzymes Market ... Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), Crop-type & Geography - ... Enzymes Market is expected to reach $489.05 Million by ... 2020. Browse 75 market Tables and ... P ages and an in-depth TOC on ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
Cached News: